Scholarlink

<p>This randomized, double-blind clinical trial assessed the clinical and microbiological effects of systemic azithromycin (AZ) as an adjunct to one-stage full-mouth disinfection (OSFMD) in patients with moderate to severe chronic periodontitis. Forty-two patients were assigned to OSFMD with either AZ or placebo. Clinical parameters and bacterial counts were evaluated at baseline, 90, and 180&#xa0;days. Both groups showed significant reductions in probing pocket depth (PPD), attachment loss, bleeding, and plaque scores over time; however, no statistically significant intergroup differences were observed in clinical outcomes (p &gt; 0.05). In contrast, the AZ group showed a statistically significant reduction in total bacterial counts and specific periodontopathogens (p &lt; 0.05). Oral health-related quality of life (OHQOL) improved significantly in both groups 2&#xa0;weeks post-treatment. Although AZ provided enhanced microbiological benefits, its adjunctive use did not yield additional clinical improvements. These findings suggest that routine use of AZ may not be justified for all patients undergoing OSFMD, though benefits may exist for selected high-risk cases. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical evaluation of full mouth disinfection and azithromycin in chronic periodontitis: randomized clinical trial

  • 期刊论文

  • 发表日期：

    2025年4月30日

查看全文
  • Eman Elhassan,
  • Julio Rincon,
  • Lavanya A. Sharma,
  • Ajay Sharma,
  • Wang Lai Hui,
  • Alessandro Quaranta

摘要

This randomized, double-blind clinical trial assessed the clinical and microbiological effects of systemic azithromycin (AZ) as an adjunct to one-stage full-mouth disinfection (OSFMD) in patients with moderate to severe chronic periodontitis. Forty-two patients were assigned to OSFMD with either AZ or placebo. Clinical parameters and bacterial counts were evaluated at baseline, 90, and 180 days. Both groups showed significant reductions in probing pocket depth (PPD), attachment loss, bleeding, and plaque scores over time; however, no statistically significant intergroup differences were observed in clinical outcomes (p > 0.05). In contrast, the AZ group showed a statistically significant reduction in total bacterial counts and specific periodontopathogens (p < 0.05). Oral health-related quality of life (OHQOL) improved significantly in both groups 2 weeks post-treatment. Although AZ provided enhanced microbiological benefits, its adjunctive use did not yield additional clinical improvements. These findings suggest that routine use of AZ may not be justified for all patients undergoing OSFMD, though benefits may exist for selected high-risk cases.